The World Health Organisation it is getting rid of hydroxychloroquine from its worldwide research study of prospective COVID-19 treatments while it performs an evaluation of its safety.
Last week President Trump said he was taking the anti-malarial drug, which he has promoted as offering possible security from coronavirus, in spite of cautions from health authorities that it could cause heart issues.
The decision by the WHO to temporarily suspend hydroxychloroquine from its research study follows a paper published in The Lancet recently which suggested it might in fact increase the danger for COVID-19 patients.
In a research study of 96,000 coronavirus clients, practically 15,000 were provided hydroxychloroquine – or an associated form chloroquine – either alone or with an antibiotic.
It found that the death rates for those being dealt with were: hydroxychloroquine 18%; chloroquine 16.4%; control group 9%. Those treated with hydroxychloroquine or chloroquine in combination with prescription antibiotics had an even higher death rate.
WHO director-general Tedros Adhanom Ghebreyesus said that because of the research there would be “a temporary pause” on the hydroxychloroquine arm of its global scientific trial.
Other treatments in the research study, including the speculative antiviral drug remdesivir, which was initially established to fight ebola, and an HIV combination treatment, are still being pursued.
When asked about his usage of the drug by Sinclair Broadcast Group’s Sharyl Attkisson, he said: “Well, I’ve heard incredible reports about it.
” You had a study in France, you had a study in Italy that were unbelievable studies.
” I don’t get anything.